Cardiac Resynchronization Therapy for End-Stage Hypertrophic Cardiomyopathy

Cardiac resynchronization therapy (CRT) is a well-established treatment for patients with heart failure (HF) with reduced left ventricular ejection fraction (LVEF), whereas its role in patients with preserved LVEF is controversial at best [(1)][1]. Hypertrophic cardiomyopathy (HCM) is characterized